1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsCore Grants (Gateway for Cancer Research) is sponsored by Gateway for Cancer Research. These core grants fund early-phase clinical trials for all types of cancers at renowned institutions around the world. Gateway for Cancer Research focuses on patient-centric research, supporting translational research through clinical trials.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
GFCR All Grant Programs - Gateway for Cancer Research Gateway for Cancer Research Gateway Traditional Grant Program Core grants funding early phase clinical trials for cancers of all types at renowned institutions around the world. These grants are typically 2-5 years in duration with award amounts from $200,000 to $1. 5 million.
Joint NCI/ SPORE/ P20 Program Our collaboration with the National Cancer Institute (NCI)/Specialized Programs of Research Excellence (SPORE)/ P20 Program allows us to fund more patient-centric research.
Gateway collaborates with the NCI seeking proposals from SPORE and P20 awardees that could enable principal investigators and their respective institutions to expand a clinical trial by adding an additional arm, adding new patient cohorts to an existing clinical trial, generating new correlative analysis, and/or expand the study sample size by enrolling additional patients. Funding cannot duplicate the scope of work of the SPORE award.
This grant program will support translational research through clinical trials conducted by institutions that receive NCI SPORE awards. Gateway will issue grant awards based on an application and review process conducted by Gateway. Gateway focuses on funding integrative oncology research that pairs conventional therapies with evidence-based, complementary therapies to manage symptoms and side effects from treatment.
This also aims to increase quality of life during treatment.
Joint Society for Integrative Oncology (SIO) Program (FGAs Reviewed Once Annually) Our collaboration with the Society for Integrative Oncology (SIO) allows us to bring the most promising patient-centered, integrative oncology research proposals forward, Gateway collaborates with SIO to support integrative clinical trials conducted by principal investigators and institutions among its membership.
SIO’s mission is to advance evidence-based, comprehensive, integrative healthcare to improve the lives of people affected by cancer. LOIs will be accepted year-round; however, FGA invitations will only be sent out once yearly in correspondence with the Spring Gateway/SIO peer review meeting.
Decentralized Clinical Trial Initiative (DCTI) During the COVID-19 pandemic, we launched a new grant program to fund research leveraging site-less, technology-informed trials, with the objective of bringing clinical trials directly to patients’ doorsteps.
Successful DCTI proposals should: Advance a treatment-based clinical trial in oncology Emphasize the delivery of the investigational treatment in a decentralized setting, ideally home-based Define compelling primary and secondary endpoints Creatively leverage one or more innovative technologies (telemedicine, wearables, remote monitoring, medical record review, e-consent, etc.) Have been reviewed with your CTO Administrative Director for regulatory, data management, and safety considerations related to implementation Integrate mobile clinician management, as needed Incorporate rigorous and methodical collection, management, and analysis of trial-related data Utilize clinical resources in proximity and convenient to patients for any trial-related procedures that cannot practicably be carried out in a decentralized setting (e.g. imaging, interventional radiology, complex infusion, etc.) Leverage strategic inter- and/or intra-institutional collaboration, including commercial (e.g. biopharmaceutical, CRO, home health companies, etc.) Our collaboration with the Eastern Cooperative Oncology Group – American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group allows us to expand innovative phase II trials into the community.
ECOG-ACRIN has a network comprised of nearly 1,400 academic and community-based cancer centers and hospitals. Their mission is to reduce the burden of cancer and improve the quality of life and survival of adult patients with cancer. Special Request for Applications (RFAs) Please see the eligibility quiz for any open RFAs.
LOI submissions due - current cycle November 6, 2026 at 12 pm CT (tentative) FGA submissions due - current cycle Gateway Traditional Grant Program Core grants funding early phase clinical trials for cancers of all types at renowned institutions around the world. These grants are typically 2-5 years in duration with award amounts from $200,000 to $1. 5 million.
Joint NCI/ SPORE/ P20 Program Our collaboration with the National Cancer Institute (NCI)/Specialized Programs of Research Excellence (SPORE)/ P20 Program allows us to fund more patient-centric research.
Gateway collaborates with the NCI seeking proposals from SPORE and P20 awardees that could enable principal investigators and their respective institutions to expand a clinical trial by adding an additional arm, adding new patient cohorts to an existing clinical trial, generating new correlative analysis, and/or expand the study sample size by enrolling additional patients. Funding cannot duplicate the scope of work of the SPORE award.
This grant program will support translational research through clinical trials conducted by institutions that receive NCI SPORE awards. Gateway will issue grant awards based on an application and review process conducted by Gateway. Gateway focuses on funding integrative oncology research that pairs conventional therapies with evidence-based, complementary therapies to manage symptoms and side effects from treatment.
This also aims to increase quality of life during treatment.
Joint Society for Integrative Oncology (SIO) Program (FGAs Reviewed Once Annually) Our collaboration with the Society for Integrative Oncology (SIO) allows us to bring the most promising patient-centered, integrative oncology research proposals forward, Gateway collaborates with SIO to support integrative clinical trials conducted by principal investigators and institutions among its membership.
SIO’s mission is to advance evidence-based, comprehensive, integrative healthcare to improve the lives of people affected by cancer. LOIs will be accepted year-round; however, FGA invitations will only be sent out once yearly in correspondence with the Spring Gateway/SIO peer review meeting.
Decentralized Clinical Trial Initiative (DCTI) During the COVID-19 pandemic, we launched a new grant program to fund research leveraging site-less, technology-informed trials, with the objective of bringing clinical trials directly to patients’ doorsteps.
Successful DCTI proposals should: Advance a treatment-based clinical trial in oncology Emphasize the delivery of the investigational treatment in a decentralized setting, ideally home-based Define compelling primary and secondary endpoints Creatively leverage one or more innovative technologies (telemedicine, wearables, remote monitoring, medical record review, e-consent, etc.) Have been reviewed with your CTO Administrative Director for regulatory, data management, and safety considerations related to implementation Integrate mobile clinician management, as needed Incorporate rigorous and methodical collection, management, and analysis of trial-related data Utilize clinical resources in proximity and convenient to patients for any trial-related procedures that cannot practicably be carried out in a decentralized setting (e.g. imaging, interventional radiology, complex infusion, etc.) Leverage strategic inter- and/or intra-institutional collaboration, including commercial (e.g. biopharmaceutical, CRO, home health companies, etc.) Our collaboration with the Eastern Cooperative Oncology Group – American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group allows us to expand innovative phase II trials into the community.
ECOG-ACRIN has a network comprised of nearly 1,400 academic and community-based cancer centers and hospitals. Their mission is to reduce the burden of cancer and improve the quality of life and survival of adult patients with cancer. Special Request for Applications (RFAs) Please see the eligibility quiz for any open RFAs.
LOI submissions due - current cycle November 6, 2026 at 12 pm CT (tentative) FGA submissions due - current cycle
According to the current listing, eligibility includes: Renowned institutions around the world (implies universities are eligible). Confirm the full requirements in the official notice before applying.
The current listing shows $200,000 to $1.5 million over 2-5 years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Core Grants (Gateway for Cancer Research) is funded by Gateway for Cancer Research. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articleCDC-RFA-DP-27-0023 puts the National Breast and Cervical Cancer Early Detection Program, the National Comprehensive Cancer Control Program, and the National Program of Cancer Registries into a single competition closing February 5, 2027. Three statutorily separate eligibility pools, one application deadline, and an award count that maps onto the incumbent footprint. Here is how to read that.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read article